Six years after SARS-CoV-2 emerged, researchers are no longer asking whether patients are sick. They are trying to understand why the same infection can leave one person with debilitating fatigue, […]
NIH RECOVER Clinical Trials and the First Emergence of Interventional Results in Long COVID Research: A Translational Turning Point
A Scholarly Review for Scientific American (Submission-Style Manuscript) John Murphy, M.D., M.P.H., D.P.H., President, COVID-19 Long-Haul Foundation Abstract The NIH RECOVER Initiative represents the largest coordinated research program investigating post–acute […]
Developing a general research framework for long COVID using causal modelling
Abstract Background Long COVID is an infection-associated chronic condition with uncertain evolution, leading to ambiguity in case definitions and various hypotheses about its pathophysiology. Despite this diversity, causal models may […]
Study suggests long COVID is more prevalent than previously thought
OHSU research in nonhuman primates finds long-term effects in both lean and obese animals By Erik Robinson July 24, 2025 Portland, Oregon Exposure to the virus that causes COVID-19 may lead to chronic […]
A year of discovery: Looking back at 2025 and ahead to 2026
In 2025, RECOVER used many different study methods to understand who is most impacted by Long COVID and why the condition develops. In 2025, the RECOVER Initiative continued to make […]
Big Pharma Giants Pfizer and BioNTech Forced to Shut Down COVID-19 Booster Shot Trials After Americans Refuse to Be Guinea Pigs
by Jim Hᴏft Major Big Pharma companies have abruptly halted their latest COVID-19 mRNA “booster” trial because they literally couldn’t find enough willing participants. After years of gaslighting the American public, […]
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Authored by Ben Sellers via Headline USA, Two of the major pharmaceutical companies connected with the controversial COVID vaccines were forced to abandon a new research study after failing to garner enough participants. Pfizer and German vax maker […]
Characterization of PASC and investigation of biomarkers: Insights from the RECOVER adult cohort
RECOVER researchers shared how biomarkers and the RECOVER-Adult Long COVID Research Index can help researchers understand, diagnose, prevent, and treat Long COVID. During the February 11th RECOVER Research Review (R3) […]
Pharmacologic Management of Long COVID: Mechanisms, Therapeutics, Risks, and Emerging Clinical Trials
John Murphy, CEO, The Covid-Long haul Foundation Abstract Long COVID (Post-Acute Sequelae of SARS-CoV-2 infection, PASC) is a heterogeneous, multi-system disorder characterized by persistent symptoms following acute infection. Affecting tens […]
Understanding metformin use and Long COVID and ME/CFS
RECOVER researchers shared how the prescription drug metformin may reduce the risk of Long COVID and presented research examining the risk of developing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after a […]